Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22549094 | 0.83 | MAPK1 (0.31) | MAPK1GAA | |
| SCHEMBL6184867 | 0.75 | SLC6A2 (0.42) | MAPK1 | |
| SCHEMBL15888824 | 0.74 | MAPK1 (0.33) | MAPK1GAAMAPTSMN1; SMN2 | |
| SCHEMBL15998439 | 0.73 | SMN1; SMN2 (0.34) | MEN1MAPTKMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL19507966 | 0.72 | GAA (0.33) | MAPK1GAAMAPTSMN1; SMN2 | |
| SCHEMBL21610744 | 0.72 | MAPK1 (0.33) | MAPK1GAAMAPTSMN1; SMN2 | |
| SCHEMBL2389630 | 0.72 | MAPK1 (0.33) | MAPK1GAAMAPTSMN1; SMN2 | |
| SCHEMBL21610742 | 0.72 | MAPK1 (0.33) | MAPK1GAAMAPTSMN1; SMN2 | |
| SCHEMBL21610738 | 0.71 | MAPK1 (0.38) | MAPK1 | |
| SCHEMBL21610732 | 0.71 | MAPK1 (0.35) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020002090-A1 | SUBSTITUTED THIAZOLYLPYRROLONES, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-02 | — | — | WO | disclosed |
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | IAPP, INSR, AMY2A | MAPK1 2535/4885GAA 419/4885MEN1 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.